Patents by Inventor Dennis J. Slamon

Dennis J. Slamon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8007995
    Abstract: The invention described herein relates to methods and compositions useful in the diagnosis, treatment and management of cancers that express particular genes, including the moesin, caveolin 1, and/or yes-associated protein 1 genes.
    Type: Grant
    Filed: November 10, 2006
    Date of Patent: August 30, 2011
    Assignees: Bristol-Myers Squibb Company, The Regents of the University of California
    Inventors: Richard S. Finn, Judy Dering, Dennis J. Slamon, Charles L. Ginther, Edwin A. Clark
  • Publication number: 20110166154
    Abstract: Methods and compositions are provided useful in the diagnosis, treatment and management of cancers wherein cancer cells express certain polynucleotides and/or polypeptides that are differentially expressed in colon cancer subtypes that are sensitive to therapy with abl kinase inhibitors and src kinase inhibitors. In particular, PTK-7, PLK-2 and PLK-3 could be identified as markers for determining the responsiveness of cancer to dasatinib.
    Type: Application
    Filed: January 23, 2009
    Publication date: July 7, 2011
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Dennis J. Slamon, Richard S. Finn, Judy Dering, J. Randolph Hecht, Zev A. Wainberg, Edwin A. Clark, Charles L. Ginther
  • Publication number: 20090170866
    Abstract: The invention described herein relates to methods and compositions useful in the diagnosis, treatment and management of cancers that express particular genes, including the moesin, caveolin 1, and/or yes-associated protein 1 genes.
    Type: Application
    Filed: November 10, 2006
    Publication date: July 2, 2009
    Applicants: Bristol-Myers Squibb Pharma Company, The Regents of the University of California
    Inventors: Richard S. Finn, Judy Dering, Dennis J. Slamon, Charles L. Ginther, Edwin A. Clark
  • Patent number: 7537905
    Abstract: This invention relates to methods to diagnose colon cancer and other proliferative diseases. Gene 26#77 is identified herein as a novel oncogene. Methods are provided for diagnosing and treating a disease or disorder characterized by amplification of the 26#77 gene and/or overexpression of 26#77 gene products. The 26#77 gene is located on chromosome 20q13.2, a region whose amplification is associated with a poor cancer prognosis. The 26#77 gene is amplified and 26#77 RNA and protein are overexpressed in 60% of colorectal cancers.
    Type: Grant
    Filed: January 15, 2003
    Date of Patent: May 26, 2009
    Assignee: The Regents of the University of California
    Inventors: Dennis J. Slamon, Lee A. Anderson, Charles L. Ginther
  • Publication number: 20080318212
    Abstract: Methods and materials relating to the orphan receptor tyrosine kinase (ROR1) are described. ROR1 exhibits restricted tissue expression in normal adult tissue and is overexpressed in certain breast cancer subtypes. ROR1 provides a diagnostic and/or therapeutic target for breast cancers.
    Type: Application
    Filed: April 6, 2005
    Publication date: December 25, 2008
    Inventors: Cindy A. Wilson, Judy Dering, Dennis J. Slamon
  • Patent number: 7314916
    Abstract: The disclosure provided herein identifies and characterizes the domain in HER3 receptor that interacts with heregulin ligand. Typical embodiments of the invention disclosed herein include HER3 variant polypeptides having amino acid sequences which differ from the native HER3 polypeptide sequence and which have altered affinities for heregulin. Also disclosed herein are methods and materials for identifying compounds that bind to the heregulin binding domain in HER3 as well as methods and materials for modulating the interaction between HER3 and heregulin.
    Type: Grant
    Filed: April 19, 2006
    Date of Patent: January 1, 2008
    Assignee: The Regents of the University of California
    Inventors: Elizabeth Singer, Ralf Landgraf, Dennis J. Slamon, David Eisenberg
  • Patent number: 7125680
    Abstract: The disclosure provided herein identifies and characterizes the domain in HER3 receptor that interacts with heregulin ligand. Typical embodiments of the invention disclosed herein include methods for identifying compounds which specifically bind the heregulin binding domain in HER3.
    Type: Grant
    Filed: July 29, 2002
    Date of Patent: October 24, 2006
    Assignee: The Regents of the University of California
    Inventors: Elizabeth Singer, Ralf Landgraf, Dennis J. Slamon, David Eisenberg
  • Patent number: 6929910
    Abstract: The present invention relates to the identification of the H37 tumor suppressor gene and methods of diagnosing and treating a disease or disorder characterized by abnormal cellular proliferation, such as a tumor or cancer. Diagnosis is accomplished examining or monitoring cells for perturbations in H37 expression or function. Treatment is accomplished by inserting a host cell compatible H37 expression vector or an effective amount of H37 protein into a cell or cells in need of treatment.
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: August 16, 2005
    Assignee: The Regents of the University of California
    Inventors: Dennis J. Slamon, Juliana J. Oh
  • Patent number: 6893837
    Abstract: The invention disclosed herein improves upon existing tissue microarray technology by using frozen tissues embedded in tissue embedding compound as donor samples and arraying the specimens into a recipient block comprising tissue embedding compound. Tissue is not fixed prior to embedding, and sections from the array are evaluated without fixation or post-fixed according to the appropriate methodology used to analyze a specific gene at the DNA, RNA, and/or protein levels. Unlike paraffin tissue arrays which can be problematic for immunohistochemistry and for RNA in situ hybridization analyses, the disclosed methods allow optimal evaluation by each technique and uniform fixation across the array panel. The disclosed arrays work well for DNA, RNA, and protein analyses, and have significant qualitative and quantitative advantages over existing methods.
    Type: Grant
    Filed: February 23, 2004
    Date of Patent: May 17, 2005
    Assignee: The Regents of the University of California
    Inventors: Dennis J. Slamon, Marlena Schoenberg Fejzo
  • Publication number: 20040171101
    Abstract: The invention disclosed herein improves upon existing tissue microarray technology by using frozen tissues embedded in tissue embedding compound as donor samples and arraying the specimens into a recipient block comprising tissue embedding compound. Tissue is not fixed prior to embedding, and sections from the array are evaluated without fixation or post-fixed according to the appropriate methodology used to analyze a specific gene at the DNA, RNA, and/or protein levels. Unlike paraffin tissue arrays which can be problematic for immunohistochemistry and for RNA in situ hybridization analyses, the disclosed methods allow optimal evaluation by each technique and uniform fixation across the array panel. The disclosed arrays work well for DNA, RNA, and protein analyses, and have significant qualitative and quantitative advantages over existing methods.
    Type: Application
    Filed: February 23, 2004
    Publication date: September 2, 2004
    Applicant: The Regents of the University of California
    Inventors: Dennis J. Slamon, Marlene Schoenberg Fejzo
  • Patent number: 6770477
    Abstract: The present invention provides human Her-2/neu overexpression modulated proteins (HOMPS) and polynucleotides encoding HOMPS polypeptides. The invention also provides HOMPS containing expression vectors and host cells, HOMPS antibodies and methods of producing HOMPS. In addition, the invention provides methods for generating, identifying and manipulating HOMPS.
    Type: Grant
    Filed: October 5, 2000
    Date of Patent: August 3, 2004
    Assignee: The Regents of the University of California
    Inventors: Dennis J. Slamon, Juliana J. Oh
  • Patent number: 6767541
    Abstract: The present invention provides methods for obtaining genetic profiles of cancer cells in order to assess the status of a cancer in an individual. In addition, the present invention provides methods for inhibiting the growth of cancer cells that exhibit certain genetic profiles. These methods identify an important link between HER-2/neu overexpression and loss of growth inhibition by the TGF-&bgr; signaling pathway in cancer cells. Compositions as well as therapeutic and diagnostic methodologies based on this disclosure are provided.
    Type: Grant
    Filed: March 20, 2001
    Date of Patent: July 27, 2004
    Assignees: The Regents of the University of California, Amgen Inc.
    Inventors: Dennis J. Slamon, Cindy A. Wilson, Frank J. Calzone
  • Publication number: 20040137442
    Abstract: This invention relates to methods to diagnose colon cancer and other proliferative diseases. Gene 26#77 is identified herein as a novel oncogene. Methods are provided for diagnosing and treating a disease or disorder characterized by amplification of the 26#77 gene and/or overexpression of 26#77 gene products. The 26#77 gene is located on chromosome 20q13.2, a region whose amplification is associated with a poor cancer prognosis. The 26#77 gene is amplified and 26#77 RNA and protein are overexpressed in 60% of colorectal cancers.
    Type: Application
    Filed: January 15, 2003
    Publication date: July 15, 2004
    Applicant: REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Dennis J. Slamon, Lee A. Anderson, Charles L. Ginther
  • Patent number: 6696271
    Abstract: The invention disclosed herein improves upon existing tissue microarray technology by using frozen tissues embedded in tissue embedding compound as donor samples and arraying the specimens into a recipient block comprising tissue embedding compound. Tissue is not fixed prior to embedding, and sections from the array are evaluated without fixation or post-fixed according to the appropriate methodology used to analyze a specific gene at the DNA, RNA, and/or protein levels. Unlike paraffin tissue arrays which can be problematic for immunohistochemistry and for RNA in situ hybridization analyses, the disclosed methods allow optimal evaluation by each technique and uniform fixation across the array panel. The disclosed arrays work well for DNA, RNA, and protein analyses, and have significant qualitative and quantitative advantages over existing methods.
    Type: Grant
    Filed: August 23, 2001
    Date of Patent: February 24, 2004
    Assignee: The Regents of the University of California
    Inventors: Dennis J. Slamon, Marlena Schoenberg Fejzo
  • Publication number: 20030225008
    Abstract: The present invention relates to the identification of the H37 tumor suppressor gene and methods of diagnosing and treating a disease or disorder characterized by abnormal cellular proliferation, such as a tumor or cancer. Diagnosis is accomplished examining or monitoring cells for perturbations in H37 expression or function. Treatment is accomplished by inserting a host cell compatible H37 expression vector or an effective amount of H37 protein into a cell or cells in need of treatment.
    Type: Application
    Filed: September 21, 2001
    Publication date: December 4, 2003
    Applicant: The Regents of the University of California
    Inventors: Dennis J. Slamon, Juliana J. Oh
  • Publication number: 20030143568
    Abstract: The disclosure provided herein identifies and characterizes the domain in HER3 receptor that interacts with heregulin ligand. Typical embodiments of the invention disclosed herein include HER3 variant polypeptides having amino acid sequences which differ from the native HER3 polypeptide sequence and which have altered affinities for heregulin. Also disclosed herein are methods and materials for identifying compounds that bind to the heregulin binding domain in HER3 as well as methods and materials for modulating the interaction between HER3 and heregulin.
    Type: Application
    Filed: July 29, 2002
    Publication date: July 31, 2003
    Inventors: Elizabeth Singer, Ralf Landgraf, Dennis J. Slamon, David Eisenberg
  • Publication number: 20030040035
    Abstract: The invention disclosed herein improves upon existing tissue microarray technology by using frozen tissues embedded in tissue embedding compound as donor samples and arraying the specimens into a recipient block comprising tissue embedding compound. Tissue is not fixed prior to embedding, and sections from the array are evaluated without fixation or post-fixed according to the appropriate methodology used to analyze a specific gene at the DNA, RNA, and/or protein levels. Unlike paraffin tissue arrays which can be problematic for immunohistochemistry and for RNA in situ hybridization analyses, the disclosed methods allow optimal evaluation by each technique and uniform fixation across the array panel. The disclosed arrays work well for DNA, RNA, and protein analyses, and have significant qualitative and quantitative advantages over existing methods.
    Type: Application
    Filed: August 23, 2001
    Publication date: February 27, 2003
    Applicant: The Regents of the University of California
    Inventors: Dennis J. Slamon, Marlena Schoenberg Fejzo
  • Publication number: 20020051785
    Abstract: The present invention provides methods for obtaining genetic profiles of cancer cells in order to assess the status of a cancer in an individual. In addition, the present invention provides methods for inhibiting the growth of cancer cells that exhibit certain genetic profiles. These methods identify an important link between HER-2/neu overexpression and loss of growth inhibition by the TGF-&bgr; signaling pathway in cancer cells. Compositions as well as therapeutic and diagnostic methodologies based on this disclosure are provided.
    Type: Application
    Filed: March 20, 2001
    Publication date: May 2, 2002
    Applicant: The Regents of the University of California and Amgen Inc.
    Inventors: Dennis J. Slamon, Cindy A. Wilson, Frank J. Calzone
  • Patent number: 6326148
    Abstract: The present invention provides methods of screening for colon carcinoma cells in a sample. The methods comprise providing a nucleic acid sample from a premalignant lesion in colorectal tissue from a human patient and contacting the sample with a nucleic acid probe that selectively hybridizes to a chromosomal region at 20q.
    Type: Grant
    Filed: July 12, 1999
    Date of Patent: December 4, 2001
    Assignee: The Regents of the University of California
    Inventors: Giovanni E. Pauletti, Dennis J. Slamon
  • Patent number: 5846749
    Abstract: Cellular components are quantitated using stained cell samples, computerized image analysis, and cellular standards, where the computerized image analysis value can be translated into the amount of the component per cell. The methodology is demonstrated with breast cancer cells and quantitation of the HER-2/neu gene. The quantitation is shown to have prognostic capability as to the future course of the disease.
    Type: Grant
    Filed: October 12, 1994
    Date of Patent: December 8, 1998
    Assignee: The Regents of the University of California
    Inventors: Dennis J. Slamon, Michael F. Press